Taranabant is causing a considerable buzz, an obesity drug currently in the works by the pharmaceutical giant Merck. It will be some time before this drug hits the market.
The drug is currently in the development and testing phase with a formal application to the FDA expected sometime in 2008.
So far, the results achieved by taranabant in fighting obesity have been promising, with side effects occurring only at higher doses. Reported side
effects include diarrhea, nausea, and vomiting.
Anxiety, mood swings, and depression were also reported by approximately one-quarter of those taking the highest dose in the study.
Interestingly, participants have lost weight even when taking the lowest dose tested in the trial. There are high hopes that this will be the long
sought after obesity fighting drug. The promising results come soon after the FDA did not recommend another obesity potential drug, rimonabant, for approval.
Although the producers of rimonabant have since withdrawn their application to market the drug in the United States, it is currently sold in 20 other countries.
Taranabant is a cannabinoid-1 (CB-1) drug that targets receptors in the brain that control appetite. The drug has been formulated to suppress the desire to eat and increase your metabolism. In fact, taranabant blocks the areas in the brain that are often triggered when cannabis users get the munchies.
If approved for sale, taranabant is expected to be prescribed for obese or overweight people with other health complications, and not as a diet supplement to the general public.